NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL) today announced that the first of its Phase II clinical trials of the anti-insulin-like growth factor-1 receptor (IGR-IR) monoclonal antibody IMC-A12 has commenced patient enrollment.
